EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

Krishna Jadhav iD, Ashwin Abhang iD, Eknath B Kole iD, Dipak Gadade iD, Apurva Dusane iD, Aditya Iyer, Ankur Sharma iD, Saroj Kumar Rout, Amol D Gholap iD, Jitendra Naik iD, Rahul K Verma, Satish Rojekar iD

Bioengineering · 30.04.2025 · 12 (5) · 481

DOI: 10.3390/bioengineering12050481 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 30.04.2025. Verfasst von Krishna Jadhav und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nano Science and Technology (INST), Knowledge City, Sector-81, Sahibzada Ajit Singh Nagar, Mohali 140306, Punjab, India. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide–drug conjugates (PDCs) have emerged as a next-generation therapeutic platform, combining the target specificity of peptides with the pharmacological potency of small-molecule drugs. As an evolution beyond antibody–drug conjugates (ADCs), PDCs offer distinct advantages, including enhanced cellular permeability, improved drug selectivity, and versatile design flexibility. This review provides a comprehensive analysis of the fundamental components of PDCs, including homing peptide selection, linker engineering, and payload optimization, alongside strategies to address their inherent challenges, such as stability, bioactivity, and clinical translation barriers. Therapeutic applications of PDCs span oncology, infectious diseases, metabolic disorders, and emerging areas like COVID-19, with several conjugates advancing in clinical trials and achieving regulatory milestones. Innovations, including bicyclic peptides, supramolecular architectures, and novel linker technologies, are explored as promising avenues to enhance PDC design. Additionally, this review examines the clinical trajectory of PDCs, emphasizing their therapeutic potential and highlighting ongoing trials that exemplify their efficacy. By addressing limitations and leveraging emerging advancements, PDCs hold immense promise as targeted therapeutics capable of addressing complex disease states and driving progress in precision medicine.

Schlagwörter

Stichwörter der Autor:innen

linkerspeptidepeptide–drug conjugatesstabilitytargeted therapeuticstheranostic

Autor:innen und Institutionen

  • Institute of Nano Science and Technology (INST), Knowledge City, Sector-81, Sahibzada Ajit Singh Nagar, Mohali 140306, Punjab, India.
  • Department of Pharmaceutical Sciences, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA.
  • Department of Pharmaceutical Technology, University Institute of Chemical Technology, KBC North Maharashtra University, Jalgaon 425001, Maharashtra, India.
  • Department of Pharmaceutical Sciences, Delhi Skill and Entrepreneurship University, Dwarka Campus, Sector 9 Dwarka, New Delhi 110077, Delhi, India.
  • Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
  • Biopharmaceutics Department, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore 560099, Karnataka, India.

ORCID-Profile: Krishna Jadhav, Ashwin Abhang, Eknath B Kole, Dipak Gadade, Apurva Dusane, Ankur Sharma, Amol D Gholap, Jitendra Naik, Satish Rojekar

Zitieren

APA

Jadhav, K., Abhang, A., Kole, E. B., Gadade, D., Dusane, A., Iyer, A., Sharma, A., Rout, S. K., Gholap, A. D., Naik, J., Verma, R. K., & Rojekar, S. (2025). Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress. Bioengineering, 12(5), 481. https://doi.org/10.3390/bioengineering12050481

Vancouver

Jadhav K, Abhang A, Kole EB, Gadade D, Dusane A, Iyer A, et al. Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress. Bioengineering. 2025;12(5):481. doi:10.3390/bioengineering12050481

BibTeX
@article{Jadhav2025,
  author = {Jadhav, Krishna and Abhang, Ashwin and Kole, Eknath B and Gadade, Dipak and Dusane, Apurva and Iyer, Aditya and Sharma, Ankur and Rout, Saroj Kumar and Gholap, Amol D and Naik, Jitendra and Verma, Rahul K and Rojekar, Satish},
  title = {Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress},
  journal = {Bioengineering},
  year = {2025},
  volume = {12},
  number = {5},
  pages = {481},
  doi = {10.3390/bioengineering12050481}
}
Kostenlos starten →